Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 35 (2), 163-176

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy

Affiliations
Review

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy

Anthony J Hatswell et al. Pharmacoeconomics.

Abstract

Background: Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo).

Objective: To identify and develop a taxonomic account of economic modelling approaches for pharmaceuticals licensed without RCT data.

Methods: We searched PubMed, the websites of UK health technology assessment bodies and the International Society for Pharmacoeconomics and Outcomes Research Scientific Presentations Database for assessments of treatments granted a marketing authorisation by the US Food and Drug Administration or European Medicines Agency from January 1999 to May 2014 without RCT data (74 indications). The outcome of interest was the approach to modelling efficacy data.

Results: Fifty-one unique models were identified in 29 peer-reviewed articles, 30 health technology appraisals, and 15 International Society for Pharmacoeconomics and Outcomes Research abstracts concerning 30 indications (44 indications had not been modelled). We noted the high rate of non-submission to health technology assessment agencies (28/98). The majority of models (43/51) were based on 'historical controls'-comparisons to previous meta-analysis or pooling of trials (5), individual trials (16), registries/case series (15), or expert opinion (7). Other approaches used the patient as their own control, performed threshold analysis, assumed time on treatment was added to overall survival, or performed cost-minimisation analysis.

Conclusions: There is considerable variation in the quality and approach of models constructed for drugs granted a marketing authorisation without a RCT. The most common approach is of a naive comparison to historical data (using other trials/registry data as a control group), which has considerable scope for bias.

Similar articles

See all similar articles

Cited by 1 article

  • Model Registration: A Call to Action.
    Sampson CJ, Wrightson T. Sampson CJ, et al. Pharmacoecon Open. 2017 Jun;1(2):73-77. doi: 10.1007/s41669-017-0019-2. Pharmacoecon Open. 2017. PMID: 29442337 Free PMC article. No abstract available.

References

    1. Ann Oncol. 2011 Jan;22(1):215-23 - PubMed
    1. Health Econ. 1997 May-Jun;6(3):217-27 - PubMed
    1. Value Health. 2012 Sep-Oct;15(6):940-7 - PubMed
    1. BMJ. 2007 Feb 17;334(7589):349-51 - PubMed
    1. Rev Salud Publica (Bogota). 2012 Jan-Feb;14(1):143-55 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback